# Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

> **NCT01026792** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 38 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma
- Recurrent Cervical Carcinoma
- Stage IIIA Cervical Cancer
- Stage IIIB Cervical Cancer
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer

## Interventions

- **DRUG:** Temsirolimus
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01026792
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-08
- **Final completion:** 2012-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026792, "Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01026792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*